Sinil Pharmaceutical Co. Ltd (012790) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sinil Pharmaceutical Co. Ltd (012790) has a cash flow conversion efficiency ratio of 0.017x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩2.62 Billion ≈ $1.78 Million USD) by net assets (₩151.71 Billion ≈ $102.81 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Sinil Pharmaceutical Co. Ltd defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Sinil Pharmaceutical Co. Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Sinil Pharmaceutical Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Sinil Pharmaceutical Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sinil Pharmaceutical Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zenith Minerals Ltd
AU:ZNC
|
-0.028x |
|
Obase Bilgisayar ve Danismanlik Hizmetleri Ticaret A.S.
IS:OBASE
|
0.116x |
|
Chian Hsing Forging Industrial Co Ltd
TWO:4528
|
0.041x |
|
Nanoveu Ltd
AU:NVU
|
-0.318x |
|
Goodyear (Thailand) Public Company Limited
BK:GYT
|
0.033x |
|
Kedawung Setia Industrial Tbk
JK:KDSI
|
0.025x |
|
Comunication Weaver Co.Ltd
KQ:056360
|
0.008x |
|
Atlantic International Corp. Common Stock
NASDAQ:ATLN
|
0.255x |
Annual Cash Flow Conversion Efficiency for Sinil Pharmaceutical Co. Ltd (2014–2024)
The table below shows the annual cash flow conversion efficiency of Sinil Pharmaceutical Co. Ltd from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see Sinil Pharmaceutical Co. Ltd market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩146.51 Billion ≈ $99.28 Million |
₩22.69 Billion ≈ $15.38 Million |
0.155x | +37.85% |
| 2023-12-31 | ₩134.90 Billion ≈ $91.42 Million |
₩15.15 Billion ≈ $10.27 Million |
0.112x | +1.18% |
| 2022-12-31 | ₩123.28 Billion ≈ $83.54 Million |
₩13.69 Billion ≈ $9.28 Million |
0.111x | +12.59% |
| 2021-12-31 | ₩113.20 Billion ≈ $76.71 Million |
₩11.16 Billion ≈ $7.57 Million |
0.099x | -4.18% |
| 2020-12-31 | ₩107.48 Billion ≈ $72.84 Million |
₩11.06 Billion ≈ $7.50 Million |
0.103x | -15.33% |
| 2019-12-31 | ₩101.24 Billion ≈ $68.61 Million |
₩12.31 Billion ≈ $8.34 Million |
0.122x | +25.83% |
| 2018-12-31 | ₩95.18 Billion ≈ $64.51 Million |
₩9.19 Billion ≈ $6.23 Million |
0.097x | +1.27% |
| 2017-12-31 | ₩90.93 Billion ≈ $61.62 Million |
₩8.67 Billion ≈ $5.88 Million |
0.095x | -31.23% |
| 2016-12-31 | ₩87.19 Billion ≈ $59.09 Million |
₩12.09 Billion ≈ $8.20 Million |
0.139x | +13.38% |
| 2015-12-31 | ₩78.17 Billion ≈ $52.98 Million |
₩9.56 Billion ≈ $6.48 Million |
0.122x | -7.08% |
| 2014-12-31 | ₩70.85 Billion ≈ $48.01 Million |
₩9.33 Billion ≈ $6.32 Million |
0.132x | -- |
About Sinil Pharmaceutical Co. Ltd
Sinil Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in South Korea and internationally. It offers pharmaceutical products for various indications, such as pain reliever, anti-inflammatory, hyperlipidemia, skin disease, and folic acid deficiency; and general/specialty drugs, veterinary drugs, and OEM products for various diseases. The company also provides cosmetics, incl… Read more